Pfizer soars as Trump strikes drug price deal: PFE stock rises 5.3% today: Pfizer seals Trump drug price deal with $70 billion U.S. investment and $7.3 billion Metsera weight-loss acquisition
Pfizer (PFE) stock rose about 5.3% today, closing near $25.05 per share on September 30, 2025. The stock surge followed the announcement of a landmark drug pricing deal with President Trump. The agreement includes significant drug price cuts in the U.S., the launch of the TrumpRx website for discounted medicine sales, and a massive $70 billion investment by Pfizer into U.S. research and domestic manufacturing. Additionally, Pfizer’s $7.3 billion acquisition of Metsera, a biopharma focused on weight-loss drugs, is boosting investor confidence in the obesity market outlook. These combined developments drove the strong positive market reaction to Pfizer shares today.
Pfizer Inc. (PFE) stock is currently trading around $25.12 per share as…
